Use of PDE5 Inhibitor Tied to Increased Glaucoma Risk

A large retrospective study found that men using the PDE5 inhibitor tadalafil (Cialis) for lower urinary tract symptoms had an increased likelihood of developing glaucoma-related clinical events. The association between tadalafil use and glaucoma risk was highlighted as a key finding.